Personalized Anticoagulant Therapy for Pulmonary Thromboembolism

This study develops a personalized anticoagulation (blood-thinning) strategy for special populations of patients with pulmonary embolism (blood clots in the lungs) — specifically the elderly, those with reduced kidney function, and those with active cancer — who may need different dosing than typical patients. **You may be eligible if...** - You are 18 or older and have been diagnosed with a pulmonary embolism (blood clot in the lungs), with or without deep vein thrombosis - You meet at least one of: age 75 or older, reduced kidney function (creatinine clearance below 60 mL/min), or active cancer (under treatment or not yet fully recovered) - You have not yet started blood thinner medication - Your expected survival is more than 3 months - You are willing to attend regular follow-up visits **You may NOT be eligible if...** - You have moderate to severe liver disease - You have a significant spontaneous bleeding tendency or very low platelet count - You have contraindications to blood thinners (e.g., active bleeding, known allergy to anticoagulants) - You need emergency clot-dissolving treatment (thrombolysis) for a high-risk pulmonary embolism - You are already enrolled in another clinical trial Talk to your doctor to see if this trial is right for you.